Alzheimer's in Long-Term Care--Treatment for Agitation

Alzheimer Disease Clinical Trial

Official title: Alzheimer's in Long-Term Care--Treatment for Agitation

Status Completed

Clinical Trial Summary

The purpose of this study is to see if a medication called prazosin is useful in the treatment of agitation and aggression in persons with Alzheimer's disease (AD) and other types of dementia in late life.

Clinical Trial Description

Although the occurrence of disruptive agitation behaviors likely are influenced by environmental/ interpersonal factors, it is also likely that behaviorally relevant neurobiologic abnormalities lower the threshold for the expression of such behavior in Alzheimer's disease. Because of the success prazosin has had in the treatment of Posttraumatic Stress Disorder, it is thought that it could be used similarly with disruptive agitation. Originally designed to evaluate Alzheimer's disease patients in nursing homes, the study now includes outpatients. It is a 9-week placebo-controlled trial. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease
• Psychomotor Agitation

• NCT number: NCT00161473
• Study type: Interventional
• Source: University of Washington
• Status: Completed
• Phase: N/A
• Start date: January 2001
• Completion date: September 2009